This content was released on 18/02/2021 and will expire on 18/02/2022.
The prevalence of metabolic-associated fatty liver disease (MAFLD) is estimated to be 80-90% among people with obesity, diabetes and metabolic syndrome. A notable proportion of these will progress to non-alcoholic steatohepatitis (NASH), which increases the risk of fatal and non-fatal cardiorenal disease, and is a leading indication for liver transplantation. It is therefore essential to consider MAFLD and NASH among people with metabolic diseases, including obesity and diabetes.
This 5-minute video, steered by Professor William Alazawi, summarises the pathophysiology of NASH, its links with metabolic diseases, and how it progresses to poor outcomes.